Psoriasis Clinical Trials in New York
View 83 new treatments for Psoriasis in New York, NY. Every day, Power helps hundreds of Psoriasis patients connect with leading medical research.Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, New York + 4 more
The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Deucravacitinib for Scalp Psoriasis
Bristol-Myers Squibb Clinic, Kew Gardens + 2 more
This trial is testing a medication called deucravacitinib to see if it can help people with moderate-to-severe scalp psoriasis. The medication works by blocking proteins that cause inflammation and immune responses, which are responsible for the red, itchy, and scaly patches on the scalp. The goal is to find out if this treatment is safe and effective.Show More
Subcutaneous Risankizumab for Psoriasis
AbbVie Clinic, Kew Gardens + 1 more
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is in adult participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Adverse events and change in disease signs and symptoms will be monitored. Risankizumab (Skyrizi) is a drug being studied for the treatment of moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Approximately 200 participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis will be enrolled across approximately 45 sites globally. The study will be broken up into 2 sub-studies by disease location, participants with moderate to severe genital psoriasis (Study G) and moderate to severe scalp psoriasis (Study S). In both sub-studies participants will receive subcutaneous (SC) injections of risankizumab during the 52 week treatment period, or SC injections of placebo risankizumab during the 16 week treatment period followed by SC injections of risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.Show More
Guselkumab for Psoriasis
Research Clinic, New York + 1 more
This trial tests Guselkumab, a medication that reduces inflammation, on high-risk psoriasis patients to prevent them from developing Psoriatic Arthritis. The drug works by blocking IL-23, a molecule that causes inflammation. Guselkumab is approved for treating moderate-to-severe plaque psoriasis.Show More
Methotrexate Injections for Psoriasis
Research Clinic, New York + 1 more
The investigators hope to learn the efficacy of methotrexate injections for treatment of nail psoriasis.
Skyrizi for Psoriasis
Research Clinic, New York + 1 more
Although the newly developed biologics (drugs derived from living cells cultured in a laboratory) are highly effective in controlling psoriasis, all the biologics should be continuously injected to suppress recurrence of the disease. In this regard, the observation in the phase II clinical trial conducted by us (Laboratory for Investigative Dermatology at the Rockefeller University) was groundbreaking that just a single dose of anti-IL-23p19 antibody (risankizumab, trade name: Skyrizi, study drug in this clinical trial) administration produced disease clearance up to 66 weeks in 46% (6 of 13) of patients. However, there is a lack of understanding about immune regulation in human skin induced by anti-IL-23p19 antibody injection, and there is a need to conduct a psoriasis clinical trial for single-cell sequencing immune cells in human psoriasis skin before and after anti-IL-23p19 antibody administration, and to correlate regulatory immune cell alterations with clinical disease progression. The overall objective of the clinical trial is to study regulatory immune cell alterations induced by anti-IL-23p19 antibody administration in psoriasis patients who achieve long-term disease clearance off drugs.Show More
No Placebo Trial
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, New York + 6 more
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.Show More
Bimekizumab for Psoriasis
Research Clinic, New York + 1 more
The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab in individuals with moderate-to-severe psoriasis who have failed similar therapies. Bimekizumab improves psoriasis by suppressing a type of substance found in bodies called interleukins (specifically, interleukins 17a and 17F), which are known to increase inflammation. This study will look at the effectiveness of bimekizumab in psoriasis patients that have failed previous therapies that target interleukin IL-17A or 23.Show More
No Placebo Trial
Bimekizumab for Psoriatic Arthritis
UCB Biopharma Clinic, New York + 2 more
This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.Show More
No Placebo Trial
Apremilast for Pediatric Plaque Psoriasis
Amgen Clinic, Manhasset + 2 more
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.Show More
No Placebo Trial
Frequently Asked Questions
How much do psoriasis clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.
Do I need to be insured to participate in a medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
How do psoriasis clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across psoriasis trials in New York, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for psoriasis patients is 6 Months.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.